SeabuckWonders skin care line is Certified Cruelty free. We are committed to providing certified cruelty free products from our initial ingredient selection all the way through our finished manufacturing process. Our certifying body is the Coalition for Consumer Information on Cosmetics' (CCIC) Leaping Bunny Program.
Leaping Bunny Program Certification
Leaping Bunny provides the best assurance that no current or new animal testing occurs anywhere in the manufacturing chain. Products bearing the Leaping Bunny mark are Certified Cruelty Free under the internationally recognized Humane Cosmetics or Humane Household Products Standards.
These rigorous standards stipulate that no animal testing is conducted or commissioned for finishing products or ingredients in any phase of product development by the company, its laboratories or its suppliers after a fixed cut-off date. Leaping Bunny is the most rigorous process for companies to claim they’re truly cruelty-free.
Other cruelty free logos, are more or less a promise from the company but no proof is required. Leaping Bunny requires a company to open their entire product chain for independent audit. To learn more, visit the Leaping Bunny website.
Animal Testing is Cruel and Unnecessary
These days, archaic methods of cruel animal testing are simply not needed. Scientists now have new technology like EpiSkin (a model of reconstructed human epithelium) and other testing models that make animal testing obsolete. Not to mention, animal testing is not as reliable as previously thought. According to the New England Anti-Vivisection Society:
A 2008 study in the journal Alternatives to Laboratory Animals showed that more than 80 HIV/AIDS vaccines successful in nonhuman primates failed in human trials.
According to a 2004 study in the journal Stroke, more than 4,000 studies report efficacy of more than 700 treatments of stroke in animal models. Yet none of the approximately 150 of these treatments tested in humans showed clinical benefit, as reported in a 2005 paper in the International Journal of Neuroprotection and Neuroregeneration.
Drugs intended to reduce inflammation in critically ill patients, previously tested in mice, failed in nearly 150 human critical trials according to a 2013 study in Proceedings of the National Academy of Sciences.